Skip to main content
Premium Trial:

Request an Annual Quote

Oral Cancer MDx Firm Proteocyte Closes $554K Funding

NEW YORK (GenomeWeb) – Canadian molecular diagnostics company Proteocyte Diagnostics today said that it closed a funding round that raised C$605,000 (US$554,000).

Investors included the Ontario Centres of Excellence, which provided C$250,000 in the financing, as well as a private syndicate of investors. The proceeds will be used to drive commercialization of Proteocyte's Straticyte diagnostic test for oral cancers, the Toronto-based company said. Proteocyte, which was founded in 2011, said on its website that it anticipates launching the test in 18 to 24 months.

Straticyte is a protein biomarker-based test that assesses the risk of oral lesions becoming cancerous. The biomarkers were initially discovered through proteomic research conducted at Mount Sinai Hospital and York University. Straticyte uses antibodies to first detect the biomarkers in patient samples and then software to assess them. The test compares the data from a patient with a reference database and generates a score that indicates the progression risk of a lesion.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.